08 Dec Caeregen Therapeutics Announces FDA Rare Pediatric Disease Designation for Noregen™ in the Treatment Of Familial Exudative Vitreoretinopathy (FEVR)
First potential FEVR therapy to obtain U.S. FDA Rare Pediatric Disease Designation Designation provides Noregen™ Rare Pediatric Disease Priority Review Voucher Eligibility Follows earlier Orphan Drug Designations in FEVR by both US FDA and EC EMA Caeregen Therapeutics today announced the U.S. Food and Drug Administration (FDA) designated Noregen™ for treatment...